O-1602

O-1602 is a compound that is considered a G protein-coupled receptor (GPCR) agonist. It is often associated with the G protein-coupled receptor 55 (GPR55), which is a type of GPCR that is activated by lipids and is involved in various physiological processes. O-1602 is also known to interact with the cannabinoid receptor CB1 and CB2, although it has a much lower affinity for these receptors compared to other cannabinoids.

Structure and Properties

O-1602 is a synthetic compound that is structurally similar to the natural cannabinoid cannabidiol (CBD). It has a molecular formula of C26H26O2 and a molecular weight of 374.48 g/mol. The compound is typically a white crystalline solid at room temperature.

Pharmacology

O-1602 is primarily known for its activity at the GPR55 receptor. It acts as an agonist at this receptor, meaning it can activate the receptor and trigger a physiological response. This activity is thought to be responsible for many of the effects of O-1602, although the exact mechanisms are still not fully understood.

In addition to its activity at GPR55, O-1602 also interacts with the cannabinoid receptors CB1 and CB2. However, it has a much lower affinity for these receptors compared to other cannabinoids, meaning it is less likely to activate these receptors and produce typical cannabinoid effects.

Medical Uses

While O-1602 is not currently used in any approved medical treatments, it has been the subject of research for its potential therapeutic effects. Studies have suggested that O-1602 may have anti-inflammatory and analgesic effects, and it has been investigated for potential use in conditions such as chronic pain, inflammation, and neurodegenerative diseases.

See Also

• G protein-coupled receptor 55
• Cannabinoid receptor
• Cannabidiol

O-1602 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia